Dr. Yaseen Arabi, MD, FCCP, FCCM
Chairman, Intensive Care Department, Medical Director, Respiratory Services, Professor, College
of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City
Riyadh, Kingdom of Saudi Arabia.
Dr. Arabi obtained his Internal Medicine Training at Wayne State University, Detroit, MI, USA (1992-1994), then he was the Chief Medical Resident at the same institution (1994-1995). He obtained pulmonary and critical care training at the University of Wisconsin, Madison, WI, USA (1995-1998). In 1998, he joined King Abdulaziz Medical City, Riyadh, Saudi Arabia. He is currently the Chairman of the Intensive Care Department and the Medical Director, Respiratory Services. He served as a member of several institutional committees including being the member of several international committees for the Society of Critical Care Medicine (SCCM), American College of Chest Physician (ACCP), and a member of the administrative board of the Saudi Society of Critical Care.
He received multiple grants and awards and has been an investigator on several multicenter international trials including the ADjunctive coRticosteriod trEatment iN criticAlly ilL patients with septic shock / RC12.059 (ADRENAL); Erythropoietin in Traumatic Brain Injury Study / RC10.063 (EPO-TBI); A Prospective Multicentre Randomized Controlled Trial of Early Goal Directed Sedation Compared with Standard Care in Mechanically Ventilated Patients in Intensive Care / RC-12-079 (SPICE III); Severe Acute Respiratory Infection Biological Sampling Study / RC13- 205-R (SARI); OSCILLATE Knowledge Translation – An Audit of ARDS Management / RC14/010 / MCT-04829; A multi-centre randomized controlled trial of an Open Lung Strategy Including Permissive Hypercapnia, Alveolar Recruitment and Low Airway Pressure in patients with acute respiratory distress syndrome (PHARLAP study) / CT13-005R; Prophylaxis of Thromboembolism in Critically ill Patients Using Combined Intermittent Pneumatic Compression and Pharmacologic Prophylaxis Alone: A Multicenter Randomized Controlled Trial (PTCP using CIPC & PPVPPA) / RC12/045/R (PREVENT); Middle East Respiratory Syndrome Corona Virus (MERS-CoV) RC13/244; MERS-CoV Infection Treated with a Combination of Lopinavir / Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-Blind Randomized Trial (MIRACLE Trial) RC15-142-R among the several others.
He has more than 250 publications including articles in the New England Journal of Medicine (NEJM), JAMA, Lancet, and Critical Care Medicine. He has been a reviewer for more than 40 international journals as well as granting agencies.